TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 18-70 years.~* A diagnosis of SLE according to the ACR criteria (at least 4/11 criteria).~* Sufficient signs to diagnose active SLE nephritis.~* Serum creatinine concentration of \<= 5.0 mg/dL.~* Leucocyte counts \>= 4000/uL.~* Receiving OCS (\<= 1.0 mg/kg/day; a maximum dose of 80 mg/day).~* Prior treatment with cyclophosphamide, azathioprine, cyclosporin A, or any other immunosuppressive drugs.~Exclusion Criteria:~* Chronic infection of HIV, Hepatitis B, Hepatitis C.~* Acute infection including fungal, viral, bacterial or protozoal diseases.~* Liver toxicity (WHO CTC class 2 and higher). No adequate liver function (total bilirubin \> 25 umol/L = 1.4 mg/dL unless explained otherwise (e.g. inherited, hemolysis), SGOT \> 2.5 x N, SGPT \> 2.5 x N).~* Pregnant or lactating women~* Female patients of child bearing age without safe method of contraception.~* Anemia (hemoglobin \< 8.0 g/dL), leucopenia (leucocytes \< 4000/uL unless attributable to SLE: leucocytes \< 2000/uL), thrombocytopenia (platelets \< 50000/uL).~* Neutrophils below 1000/uL.~* Hypogammaglobulinemia below 400 mg/dL of serum IgG.~* Any other condition that in the eyes of the investigator might have rendered the patient unsuitable for participation in the study. This especially includes major and active SLE organ involvement other than the kidney. Patients with SLE involvement of the central nervous system are not allowed to be included into the study.~* History of malignancy.~* Current participation in another trial or lass than 6 months since participation in a similar trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): NKT-01

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy men and women between the ages of 18 and 55~2. Positive allergen skin prick test~3. Willing and able to comply with clinic visits and study-related procedures~4. Provide signed informed consent~Exclusion Criteria:~1. Persistent, chronic, or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the screening visit~2. Any clinically significant (determined at the investigator's discretion) abnormalities observed during the screening physical examination~3. Onset of a new exercise routine or major change to a previous exercise routine within 4 weeks prior to the screening visit. Patients must be willing to maintain a similar level of exercise for the duration of the study and to refrain from unusually strenuous exercise for the duration of the trial~4. Hospitalization for any reason within 60 days prior to the screening visit~5. Participation in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives (whichever is longer) of the investigational drug prior to the screening visit~6. Any medical or psychiatric condition that in the opinion of the investigator or Regeneron, would place the patient at risk, interfere with participation in the study or interfere with the interpretation of study results~The information listed above is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial and not all inclusion/ exclusion criteria are listed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Participants in group A will receive REGN1908-1909
- Group B (Type: EXPERIMENTAL): Participants in group B will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Exposure Prophylaxis (PrEP) Provision for Ugandan Fisherfolk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for PrEP initiation:~* Tests HIV-negative at a healthcare outreach/HIV testing event in one of the two selected fishing communities and is PrEP-eligible~Exclusion Criteria:~* Not meeting the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): At the intervention site during healthcare facility outreach events, all community members will be offered the opportunity to attend intervention workshops where they can learn basic facts about PrEP and be taught skills about how to advocate for PrEP in their community. Check-in reminder calls will be conducted systematically with PrEP users. Healthcare facility staff will encourage PrEP initiators to select an adherence supporter.
- Pre-Intervention Standard of Care (Type: NO_INTERVENTION): Prior to the intervention period in the intervention community, healthcare facility staff will provide PrEP through outreach events and in local healthcare facilities according to the standard of care.
- Comparison Community (Type: NO_INTERVENTION): The comparison community will receive standard of care for PrEP provision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* documented HIV infection~* age of at least 18 years old~* HIV viral load \<400 on the most recent test~Exclusion Criteria:~* current acute moderate to severe illness (demonstrated by fever over 100.4 Fahrenheit, shortness of breath, altered mental status, or by judgment of the primary clinician)~* current pregnancy~* history of allergic reaction to a polio shot,~* history of a life-threatening allergic reaction to neomycin, streptomycin, or polymyxin B

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 2/5 dose intradermal IPV (Type: EXPERIMENTAL): Participants in this arm will receive 2/5 dose (0.2 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one-time dose intradermally using the NanoPass MicronJet 600 microneedle device
- 1/5 dose intradermal IPV (Type: EXPERIMENTAL): Participants in this study arm will receive 1/5 dose (0.1 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intradermally using the NanoPass MicronJet 600 microneedle device.
- full dose intramuscular IPV (Type: ACTIVE_COMPARATOR): Participants in this study arm will receive the standard full dose (0.5 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
- 2/5 dose intramuscular IPV (Type: ACTIVE_COMPARATOR): Participants in this study arm will receive 2/5 dose (0.2 mL) inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must provide written and informed consent.~2. Diagnosis of Bipolar II Disorder and currently depressed for minimum of the last 8 weeks, with a HAMD-17 score of at least 18 with scores of 3 or more on Items 1 or 7.~3. For females, be of non-childbearing potential, or of childbearing potential with a negative pregnancy test at screening and agrees to one of (a) abstinence from sex two weeks prior and five days after drug continuation/discontinuation, (b) personal or partner sterilization, (c) one method of hormonal contraception, or (d) two barrier methods of contraception.~4. Acceptable results (within two times the normal limit) on laboratory screening tests (e.g., thyroid function).~Exclusion Criteria:~1. Active suicidality.~2. History of non-response to antidepressant treatment, or any previous treatment with lamotrigine.~3. History of substance dependence in the past year, or abuse within the 4 weeks prior to study entry.~4. Rapid cycling bipolar disorder.~5. Receiving additional psychoactive medication (not including lorazepam for agitation), or has started a new course of psychotherapy within the last month.~6. Received treatment for an anxiety or eating disorder within the last 12 months.~7. Investigational drug use within the last month.~8. History of epilepsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamotrigine - melancholic depression (Type: EXPERIMENTAL): Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
- Placebo - melancholic depression (Type: PLACEBO_COMPARATOR): Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
- Lamotrigine - nonmelancholic depression (Type: EXPERIMENTAL): Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
- Placebo - nonmelancholic depression (Type: PLACEBO_COMPARATOR): Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Current expectation on the part of the patient's admitting intensivist for patients to require ICU care for \>/= 48 hrs~3. Administered at least one sedative dose (scheduled or prn).~Exclusion Criteria:~1. Patients with delirium (intensive care delirium screening checklist score ≥ 4) or disorientation (not oriented to person and/or place)~2. Patients in whom an ICDSC cannot be reliably completed (e.g. primary language is not French or English, baseline severe hearing impairment)~3. Inability by one of the investigators to obtain informed consent from the legally authorized representative~4. Treating physician refusal~5. Heart rate ≤ 50 BPM~6. Systolic blood pressure ≤ 90 mmHg despite the administration of norepinephrine ≥ 15 mcg/min and/or vasopressin ≥ 0.04 units/min~7. Admission with acute decompensated heart failure~8. History of heart block without pacemaker based on hospital admission note.~9. Acute alcohol withdrawal based on hospital admission note~10. History of end stage liver failure (based on presence of ≥ 1 or more of the following: AST/ALT ≥ 2 times ULN, INR ≥ 2, total bilirubin ≥ 1.5)~11. Irreversible brain disease consistent with severe dementia based on hospital admission note~12. Pregnancy (all women of child-bearing age will undergo a pregnancy test prior to study enrolment)~13. Known allergy or sensitivity to clonidine or dexmedetomidine~14. Current treatment with dexmedetomidine~p. Prognosis considered to be hopeless based on consultation with the ICU admitting physician q. Age ≥80 years r. Currently being managed with a high frequency oscillating mode (HFOV) of mechanical ventilation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Dexmedetomidine 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
- Placebo (Type: PLACEBO_COMPARATOR): Normal Saline 0.2-0.7 mcg/kg/hr from 21:30 to 6:00

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of DRX Plus 3543 and DRX Plus 3543C Digital Detectors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* X-ray images of nearly identical positioning and exposure~* No visible image artifacts~* Subject 21years or older~* Subject has provided informed consent~* Subject is in good general health~* Subject is able to stand for two (2) x-rays~Exclusion Criteria:~* Images that are not clinically acceptable for clinical radiographic reading as determined by the Principal Investigator.~* Subject is pregnant or suspicious of being pregnant~* Not able or willing to provide Informed Consent, or consent is withdrawn~* Not able to collect all required case information~* Subject has a history of high radiation exposure:~* Has undergone radiation therapy~* Has had two (2) or more CT scans within the past year

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Predicate & Invest.-GOS (Type: EXPERIMENTAL): Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
- Predicate & Invest.-CsI (Type: EXPERIMENTAL): Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
- Predicate & Invest.-Cadavers GOS & CsI (Type: EXPERIMENTAL): Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shamrock Versus Lumbar Ultrasound Trident - Ultrasound Guided Block of the Lumbar Plexus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Age ≥ 18 years~* Volunteers who have given their written and oral consent to participate in the study after fully understanding the content and the limitations of the protocol~* Normal healthy volunteer (American Society of Anesthesiology (ASA) Classification I)~Exclusion Criteria:~* Volunteers not able to cooperate for the study~* Volunteers not able to understand Danish~* Daily use of analgesics~* Allergy against the medicines used in the study~* Drug abuse (according to the investigator's judgement)~* Alcohol consumption larger than the recommendations of the Danish National Board of Health~* Volunteers in whom nerve blocks are not possible due to technical reasons~* Volunteers who meet any contraindication for MRI including claustrophobia~* Volunteers who are incompetent, i.e. surrogate consent is not accepted

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Shamrock (Type: EXPERIMENTAL): Use of the Shamrock technique to place a lumbar plexus block with injection of 20 mL 2% Lidocaine-adrenaline added gadolinium.
- Lumbar Ultrasound Trident (Type: ACTIVE_COMPARATOR): Use of the Lumbar Ultrasound Trident technique to place a lumbar plexus block with injection of 20 mL 2% lidocaine-adrenaline added gadolinium.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female child at least 24 months of age and no older than 59 months of age at the time of study vaccination.~* A child whose parent or guardian's primary residence, at the time of study vaccinations, is within the Kamalapur surveillance site catchment area or Matlab service area and who intends to be present in the area for the duration of the trial.~* A child whose parent or legal guardian is willing to provide written informed consent prior to the participant's study vaccination.~Exclusion Criteria:~* Has any serious, active, medical conditions, including: a chronic disease of any body system, chronic infections such as tuberculosis, genetic disorders, such as Down's syndrome or other cytogenetic disorder, known or suspected disease of the immune system.~* Is receiving immunosuppressive agents, including systemic corticosteroids, during the month prior to study vaccination.~* Has a history of documented hypersensitivity to eggs or other components of the vaccine (including gelatin, sorbitol, lactalbumin and chicken protein), or with life-threatening reactions to previous influenza vaccinations.~* Has ever received influenza vaccine (LAIV or inactivated).~* History of Guillain-Barre syndrome~* Is receiving aspirin therapy or aspirin-containing therapy currently or two weeks before.~* Lives in household with somebody currently participating in a respiratory vaccination or antiviral study.~* Has current or past participation (within 2 months of trial enrollment visit) in any clinical trial involving a drug or biologic with activity against respiratory disease.~* History of a previous severe allergic reaction with generalized urticarial, angioedema, or anaphylaxis.~* Has any condition determined by investigator as likely to interfere with evaluation of the vaccine or be a significant potential health risk to the child or make it unlikely that the child would complete the study~Temporary Inclusion Contraindications:~* Concurrent febrile illness (measured temperature 38 degrees C axillary).~* Active wheezing illness

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 59 Months
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients 18-75 years of age~* Kidney transplant 30-180 days post-transplantation~* Receipt of cyclosporine or tacrolimus, CellCept, and corticosteroids for greater than 14 days prior to study entry~* No known contraindications to sirolimus~Exclusion Criteria:~* Multiple organ transplant recipients or secondary kidney transplant recipients~* Corticosteroid-resistant rejection episode within 90 days prior to study entry or corticosteroid-sensitive rejection episode within 30 days prior to study entry~* More than 1 biopsy-proven episode of acute rejection prior to study entry~* Treated with sirolimus before the study~* Organ transplant or expected organ transplant, other than kidney~* History of malignancy in the last 5 years (except successfully treated localized non-melanotic skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete